title: Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.
abstract: The Birmingham Rheumatoid Arthritis Model (BRAM) has been developed over a number of years to inform several appraisals of biologic drugs by the Technology Appraisals Committee of the UK National Institute for Health and Clinical Excellence. This article describes the processes used in the construction of the different versions of the BRAM.
authors.affiliation: Health Economics Unit, School of Health and Population Sciences, Public Health Building, University of Birmingham, Birmingham, UK. p.m.barton@bham.ac.uk
authors.forename: Pelham
authors.initials: P
authors.lastname: Barton
mesh_terms: D026683:Advisory Committees; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004739:England; D019317:Evidence-Based Medicine / Q000379:methods / Q000639:trends; D006801:Humans; D015233:Models, Statistical; D011788:Quality of Life; D013673:Technology Assessment, Biomedical / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products